Vectura Group plc is a respiratory product development company. The Company focuses on the development of pharmaceutical therapies for treating airways-related diseases. The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, some of which are licensed to pharmaceutical companies. The Company’s product portfolio includes Adept, a 4% icodextrin solution used in surgery to reduce post-surgical adhesions; Advate used to treat haemophilia A; Asmasal used for rapid relief of asthma symptoms; Extraneal, a peritoneal dialysis solution containing icodextrin; Asmabec used as preventative therapy for asthma; Seebri Breezhaler, a muscarinic antagonist; Ultibro Breezhaler, a dual bronchodilator, and AirfluSal Forspiro, an inhaled combination therapy (salmeterol/fluticasone) for asthma and COPD. The Company’s pipeline products include VR588, VR611, VR942, VR475, VR465, VR647, VR179, VR736, SB010, NVA237, QVA149, VR876, VR315, VR506, and VR632.